- Home
- TOPP vs RVPH Comparison
TOPP vs RVPH Comparison
Compare TOPP & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- RVPH
- Stock Information
- Founded
- TOPP 2014
- RVPH 2006
- Country
- TOPP United States
- RVPH United States
- Employees
- TOPP N/A
- RVPH N/A
- Industry
- TOPP
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- RVPH Health Care
- Exchange
- TOPP NYSE
- RVPH Nasdaq
- Market Cap
- TOPP 26.6M
- RVPH 32.8M
- IPO Year
- TOPP 2025
- RVPH N/A
- Fundamental
- Price
- TOPP $1.68
- RVPH $0.39
- Analyst Decision
- TOPP
- RVPH Strong Buy
- Analyst Count
- TOPP 0
- RVPH 5
- Target Price
- TOPP N/A
- RVPH $9.00
- AVG Volume (30 Days)
- TOPP 6.1K
- RVPH 3.7M
- Earning Date
- TOPP 08-11-2025
- RVPH 08-13-2025
- Dividend Yield
- TOPP N/A
- RVPH N/A
- EPS Growth
- TOPP N/A
- RVPH N/A
- EPS
- TOPP N/A
- RVPH N/A
- Revenue
- TOPP $16,117,227.00
- RVPH N/A
- Revenue This Year
- TOPP N/A
- RVPH N/A
- Revenue Next Year
- TOPP N/A
- RVPH N/A
- P/E Ratio
- TOPP N/A
- RVPH N/A
- Revenue Growth
- TOPP 0.44
- RVPH N/A
- 52 Week Low
- TOPP $0.97
- RVPH $0.30
- 52 Week High
- TOPP $4.50
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- RVPH 35.25
- Support Level
- TOPP N/A
- RVPH $0.38
- Resistance Level
- TOPP N/A
- RVPH $0.45
- Average True Range (ATR)
- TOPP 0.00
- RVPH 0.05
- MACD
- TOPP 0.00
- RVPH 0.01
- Stochastic Oscillator
- TOPP 0.00
- RVPH 56.31
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.